Suggested remit: To appraise the clinical and cost effectiveness of sugemalimab within its marketing authorisation for untreated metastatic non-small-cell lung cancer.
Status Awaiting development
Process TAG
ID number 4001

Project Team

Project lead Michelle Adhemar

Email enquiries


Key events during the development of the guidance:

Date Update
06 October 2021 - 27 October 2021 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance